Medicare-eligible patients need to be enrolled in registry to get Medicare coverage for the anti-beta amyloid drug that is priced to cost $26,500 a year.
Peter Wehrwein
Advertisement
Articles by Peter Wehrwein
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
CEVA Logistics Expands End-to-End Capabilities With Acquisition of Project Logistics Specialist Fagioli
2
Novartis’ $23 Billion Manufacturing Investment Anchors Industry Shift Toward US Onshoring
3
Trade & Channel Strategies 2025: Why Product-Level Strategy Matters More Than Ever
4
Pharma Pulse: The ACA Subsidy Cliff and New Frontiers for GLP-1s
5